• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Assessment of pre-specified adverse events following varicella vaccine: A population-based self-controlled risk interval study.
CONCLUSIONS: We detected a small risk of incidental pneumonia associated with varicella vaccine in the 6th week after immunization. There was no increase in the risk of other pre-specified adverse events. PMID: 32046891 [PubMed - as supplied by publisher]
Source: Vaccine - February 7, 2020 Category: Allergy & Immunology Authors: Liu CH, Yeh YC, Huang WT, Chie WC, Chan KA Tags: Vaccine Source Type: research

What Causes Microcephaly?
Discussion Microcephaly is usually defined as an occipitofrontal head circumference (OFC) more than 2 standard deviations (SD) below the mean for sex, age and ethnicity. Severe microcephaly is used for OFC < 3 standard deviations. Rates of microcephaly range from 0.5-12 patients/10,000 live births. The OFC should be measured at every well child visit and at other opportunities and plotted on standard growth charts. The OFC is measured using a nonelastic tape measure around the largest part of the head with the tape measure held above the eyebrows and ears. It is a highly reproducible measurement. There are several diff...
Source: PediatricEducation.org - September 25, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Central Nervous System Complications of Varicella-Zoster Virus
Conclusion: Neurologic complications of VZV infection continue to occur despite the availability of an effective vaccine. Neurologic symptom onset can predate the appearance of the VZV exanthem and in rare cases may occur in the absence of an exanthem.
Source: The Journal of Pediatrics - July 24, 2014 Category: Pediatrics Authors: Michelle Science, Daune MacGregor, Susan E. Richardson, Sanjay Mahant, Dat Tran, Ari Bitnun Tags: Original Articles Source Type: research

Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.
CONCLUSIONS: In this safety surveillance study of more than 200,000 DTaP-IPV vaccine recipients, there was no evidence of increased risk for any of the pre-specified adverse events monitored. Continued surveillance of DTaP-IPV vaccine safety may be warranted to monitor for rare adverse events, such as Guillain-Barré syndrome. PMID: 24699471 [PubMed - as supplied by publisher]
Source: Vaccine - March 31, 2014 Category: Allergy & Immunology Authors: Daley MF, Yih WK, Glanz JM, Hambidge SJ, Narwaney KJ, Yin R, Li L, Nelson JC, Nordin JD, Klein NP, Jacobsen SJ, Weintraub E Tags: Vaccine Source Type: research